NPPB and poikiloderma with neutropenia: Treatment with patisiran, currently only approved for treating ATTR polyneuropathy (ATTR-PN), also might be associated with cardiac amyloid regression in a proportion of patients, as evidenced by reduced extracellular volume and disease stabilization with significant differences in NT-proBNP, left ventricular wall thickness, global longitudinal strain, and cardiac output.